Meda AB (publ) – 2010 year-end report
· Meda exceeds published full-year forecast for 2010. · Group sales reach SEK 11,571 million (13,178). Currency effects and generic competition for the Astelin and Optivar products are the most important reasons for decreased sales compared with last year. · EBITDA amounts to SEK 4,306 million (4,387), corresponding to a 37.2% margin (33.3). · EBITDA, excluding non-recurring effects[1] and currency effects, is SEK 4,432 million (4,518), thus yielding a 35.3% margin (34.3). · Operating profit amounts to SEK 2,529 million (2,902).